Practical application of anti-TNF therapy for luminal Crohn's disease

Inflammatory Bowel Diseases

Volumn 17, Issue 11, 2011, Pages 2366-2391

  Kamm, Michael A ^a,b   Ng, Siew C ^a,c   De Cruz, Peter ^a   Allen, Patrick ^a   Hanauer, Stephen B ^d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

adalimumab; anti TNF; biologic therapy; certolizumab; Crohn's disease; infliximab; loss of response; remission; response

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PREDNISOLONE; TACROLIMUS; THALIDOMIDE;

ABSCESS; BREAST FEEDING; COHORT ANALYSIS; CROHN DISEASE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; OPPORTUNISTIC INFECTION; OSTEOMYELITIS; PATIENT COMPLIANCE; PNEUMONIA; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; REVIEW; SYSTEMATIC REVIEW; T CELL LYMPHOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; ULCER HEALING;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054754787     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21655     Document Type: Review

References (158)

1. Kamm MA, Ng SC,. Perianal fistulizing Crohn's disease: a call to action. Clin Gastroenterol Hepatol. 2008; 6: 7-10. (Pubitemid 50008422)
2. Panaccione R, Rutgeerts P, Sandborn WJ, et al. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008; 28: 674-688.
3. Ng SC, Kamm MA,. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis. 2009; 15: 935-950.
4. Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007; 133: 312-339. (Pubitemid 47031141)
5. Rutgeerts P, Vermeire S, Van Assche G,. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009; 136: 1182-1197.
6. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70: 439-444.
7. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337: 1029-1035.
8. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549. (Pubitemid 34621118)
9. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228-238. (Pubitemid 47080387)
10. Abreu MT,. Crohn's disease in patients who fail infliximab therapy: what does the future hold? Rev Gastroenterol Disord. 2007; 7 (suppl 1): S20-S26. (Pubitemid 46355548)
11. Panaccione R,. Response after 12 weeks of adalimumab therapy in patients with Crohn's disease who were nonresponders at week 4. Am J Gastroenterol. 2008; 103 (suppl 1): S379.
12. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65. (Pubitemid 46108762)
13. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133: 412-422. (Pubitemid 47187355)
14. Mary JY, Modigliani R,. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989; 30: 983-989.
15. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004; 60: 505-512. (Pubitemid 39311530)
16. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990; 99: 956-963. (Pubitemid 20338451)
17. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut. 1984; 25: 665-672. (Pubitemid 14122134)
18. D'Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660-667. (Pubitemid 351284485)
19. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006; 63: 433-442. (Pubitemid 43261469)
20. Orlando A, Colombo E, Kohn A, et al. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis. 2005; 37: 577-583. (Pubitemid 44356070)
21. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004; 126: 402-413. (Pubitemid 38182297)
22. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004; 2: 542-553. (Pubitemid 38834038)
23. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009; 58: 492-500.
24. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130: 323-333.
25. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 1232-1239. (Pubitemid 47300424)
26. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2010; 31: 1296-1309.
27. Kamm MA, Hanauer SB, Panaccione R,. Long-term steroid-free remission in Crohn's patients receiving adalimumab: the CHARM Trial. J Crohn's Colitis. 2008; 2: 18.
28. Kamm MA, Hanauer SB, Rutgeerts P,. Results from an open-label extension of CHARM: steroid-free remission in patients with Crohn's disease who received adalimumab therapy for at least 3 years. Gastroenterology. 2009; 136:(suppl 1): A653.
29. Loftus EV, Rubin DT, Chen N, et al. Adalimumab sustains remission and quality-of-life improvements in anti-TNF-naïve patients with Crohn's disease; 3-year data from CHARM. J Crohn's Colitis. 2009; 3: S26.
30. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146: 829-838. (Pubitemid 351650483)
31. Loftus EV Jr, Feagan B, Chen N, et al. Risk of Crohn's disease-related hospitalization in patients receiving long-term adalimumab therapy: 3-year data from CHARM and ADHERE. J Crohn's Colitis. 2009; 3: S24.
32. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239-250. (Pubitemid 47080388)
33. Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010; 105: 1574-1582.
34. Lichtenstein GR, Thomsen OO, Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010; 8: 600-609.
35. Hanauer SB, Panes J, Colombel JF, et al. Clinical trial: impact of prior infliximab therapy on clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010; 32: 384-393.
36. Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010; 8: 688-695.
37. Sandborn WJ, Schreiber S, Hanauer SB, et al. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 study. Clin Gastroenterol Hepatol. 2010; 8: 696-702.
38. Cohen RD, Tsang JF, Hanauer SB,. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000; 95: 3469-3477.
39. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004; 126: 19-31. (Pubitemid 38040720)
40. Armuzzi A, Di Vincentis F, Marzo M,. Long term scheduled therapy with infliximab in inflammatory bowel disease. Gastroenterology. 2009; 1143.
41. Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther. 2009; 29: 527-534.
42. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004; 53: 849-853. (Pubitemid 38662135)
43. Poupardin C, Lemann M, Gendre JP, et al. Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. Gastroenterol Clin Biol. 2006; 30: 247-252.
44. Rudolph SJ, Weinberg DI, McCabe RP,. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci. 2008; 53: 1033-1041. (Pubitemid 351379832)
45. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395.
46. D'Haens GR, Fedorak R, Lemann M, et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1599-1604.
47. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989; 110: 353-356. (Pubitemid 19073651)
48. D'Haens G, Geboes K, Rutgeerts P,. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc. 1999; 50: 667-671. (Pubitemid 29518050)
49. Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis. 2009; 15: 375-382.
50. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1295-1301.
51. Van Moerkercke W, Ackeart C, Compenolle G,. High infliximab trough levels are associated with mucosal healing in Crohn's disease. Gastroenterology. 2010; 405.
52. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010; 138: 463-468.
53. Rutgeerts P, D'Haens G, Van Assche G, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease - first results of the EXTEND Trial. Gastroenterology. 2009; 136: A116.
54. Colombel JF, Lemann M, Bouhnik Y, et al. Endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the MUSIC clinical trial. Inflamm Bowel Dis. 2008; 14 (suppl 3): S25.
55. Gazzard BG,. The quality of life in Crohn's disease. Gut. 1987; 28: 378-381. (Pubitemid 17056869)
56. Drossman DA, Leserman J, Li ZM, et al. The rating form of IBD patient concerns: a new measure of health status. Psychosom Med. 1991; 53: 701-712.
57. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994; 106: 287-296. (Pubitemid 24041204)
58. Pallis AG, Mouzas IA,. Instruments for quality of life assessment in patients with inflammatory bowel disease. Dig Liver Dis. 2000; 32: 682-688.
59. Verissimo R,. Quality of life in inflammatory bowel disease: psychometric evaluation of an IBDQ cross-culturally adapted version. J Gastrointestin Liver Dis. 2008; 17: 439-444.
60. Ware JE Jr,. SF-36 health survey update. Spine (Phila 1976). 2000; 25: 3130-3139.
61. Lichtenstein GR, Bala M, Han C, et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis. 2002; 8: 237-243. (Pubitemid 34784975)
62. Lichtenstein GR,. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy. Am J Gastroenterol. 2005; 100: 1433-1435. (Pubitemid 41032341)
63. Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008; 103: 3132-3141.
64. Rutgeerts P, Schreiber S, Feagan B, et al. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis. 2008; 23: 289-296.
65. Feagan BG, Coteur G, Tan S, et al. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol. 2009; 104: 1976-1983.
66. Melmed GY,. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis. 2009; 15: 1410-1416.
67. Lu Y, Jacobson D, Bousvaros A,. Immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 1417-1423.
68. Rahier JF, Yazdanpanah Y, Colombel JF, et al. The European (ECCO) Consensus on infection in IBD: what does it change for the clinician? Gut. 2009; 58: 1313-1315.
69. Rahier JF, Ben-horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infection in inflammatory bowel disease. J Crohn's Colitis. 2009; 47-91.
70. Moscandrew M, Mahadevan U, Kane S,. General health maintenance in IBD. Inflamm Bowel Dis. 2009; 15: 1399-1409.
71. Kane S, Khatibi B, Reddy D,. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008; 103: 631-636. (Pubitemid 351405963)
72. Rahier JF, Yazdanpanah Y, Viget N, et al. Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2010; 31: 5-10.
73. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876-885. (Pubitemid 38252535)
74. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117: 761-769. (Pubitemid 29468216)
75. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345: 1098-1104.
76. Tubach F, Salmon-Ceron D, Ravaud P, et al. The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy. Joint Bone Spine. 2005; 72: 456-460. (Pubitemid 41821398)
77. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005; 52: 1766-1772. (Pubitemid 40852885)
78. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004; 50: 372-379. (Pubitemid 38198820)
79. Lichtenstein GR, Cohen RD, Feagan BG,. Risk factors for serious infections in patients receiving infliximab and other Crohn's disease therapies: TREAT Registry Data. Gastroenterology. 2010; T1039.
80. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005; 129: 807-818. (Pubitemid 41242673)
81. Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008; 6: 1212-1217.
82. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009; 58: 501-508.
83. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1308-1319.
84. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134: 929-936. (Pubitemid 351451967)
85. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009; 7: 874-881.
86. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007; 44: 265-267. (Pubitemid 46175082)
87. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010; 36-41.
88. Peyrin-Biroulet L, Deltenre P, de SN, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6: 644-653. (Pubitemid 351783447)
89. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995; 30: 699-706.
90. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999; 117: 49-57. (Pubitemid 29297619)
91. Henriksen M, Jahnsen J, Lygren I, et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol. 2007; 42: 602-610. (Pubitemid 46633816)
92. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001; 121: 255-260. (Pubitemid 32729372)
93. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005; 54: 237-241. (Pubitemid 40139240)
94. Etienney I, Bouhnik Y, Gendre JP, et al. Crohn's disease over 20 years after diagnosis in a referral population. Gastroenterol Clin Biol. 2004; 28: 1233-1239. (Pubitemid 40070049)
95. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008; 135: 1106-1113.
96. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001; 49: 777-782. (Pubitemid 33096034)
97. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8: 244-250. (Pubitemid 34784976)
98. Loly C, Belaiche J, Louis E,. Predictors of severe Crohn's disease. Scand J Gastroenterol. 2008; 43: 948-954.
99. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006; 130: 650-656. (Pubitemid 43374514)
100. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology. 2002; 123: 707-713. (Pubitemid 34977076)
101. Arnott ID, McNeill G, Satsangi J,. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther. 2003; 17: 1451-1457. (Pubitemid 36831435)
102. Schreiber S, Reinisch W, Colombel JF,. Early Crohn's disease shows high levels of remission to therapy with adalimumab. Gastroenterology. 2007; 132 (suppl 2): A147.
103. Reinisch W, loftberg R, Louis E, et al. Subanalysis of remission rates by duration of disease in adalimumab-treated patients with Crohn's disease: The CARE Trial. Gastroenterology. 2009; 136 (suppl 1): A523.
104. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006; 130: 1054-1061.
105. Moss AC, Kim KJ, Fernandez-Becker N, et al. Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci. 2010; 55: 1413-1420.
106. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007; 56: 1226-1231. (Pubitemid 47300423)
107. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2008; 58: S126-S135.
108. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007; 146: 406-415. (Pubitemid 351650575)
109. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348: 601-608. (Pubitemid 36204954)
110. Reinisch W, Loftberg R, Louis E, et al. Effect of concomitant steroid or immunosuppressant treatment on adalimumab response in patients with Crohn's disease: results from the Care Study. Am J Gastroenterol. 2008; 103 (suppl 1): S417.
111. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010; 59: 1363-1368.
112. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008; 134: 1861-1868. (Pubitemid 351790744)
113. Oussalah A, Chevaux JB, Fay R, et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010; 105: 1142-1149.
114. Bossuyt PJ, Juergens M, Ballet V,. Discontinuation of immunosuppressives in patients with Crohn's disease treated with scheduled maintenance infliximab: prospective long-term follow-up and influence of infliximab trough levels. Gut. 2010; 59: A80.
115. Jones JL, Loftus EV Jr,. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis. 2007; 13: 1299-1307. (Pubitemid 47597781)
116. Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr. 2005; 40: 220-222. (Pubitemid 40269746)
117. Ng SC, Plamondon S, Gupta A, et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol. 2009; 104: 2973-2986.
118. Gonzalez-Lama Y, Lopez-San RA, Marin-Jimenez I, et al. Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. Gastroenterol Hepatol. 2008; 31: 421-426.
119. Danese S, Mocciaro F, Guide LSML,. Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients who are primary non-responders or intolerant to infliximab: a real life multi-center experience of compassionate use. Gastroenterology. 2008; 134 (suppl 1): A663.
120. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007; 132: 863-873. (Pubitemid 46454266)
121. de RL, Rings EH, Damen GM, et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis. 2008; 14: 353-358. (Pubitemid 351441324)
122. Gisbert JP, Panes J,. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009; 104: 760-767.
123. Sands BE, Blank MA, Diamond RH, et al. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Aliment Pharmacol Ther. 2006; 23: 1127-1136. (Pubitemid 43779352)
124. Zabana Y, Cabre E,. Infliximab reintroduction in patients with inflammatory bowel disease previously treated with a 3-infusion induction regimen is not associated with a higher rate of immune mediated adverse effects. J Crohn's Colitis. 2008; 33.
125. Louis E, Vernier-Massouille G, Grimaud J,. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study. Gut. 2008; 57: A66.
126. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009; 137: 1628-1640.
127. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4: 1248-1254. (Pubitemid 44512213)
128. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010; 105: 1133-1139.
129. Regueiro M, Siemanowski B, Kip KE, et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis. 2007; 13: 1093-1099. (Pubitemid 47402592)
130. Sandborn WJ, Colombel JF, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011; 17: 141-151.
131. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003; 348: 24-32. (Pubitemid 36026343)
132. Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004; 99: 1984-1989. (Pubitemid 39421244)
133. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis. 2004; 10: 333-338. (Pubitemid 39029174)
134. Barthel HR, Gille T, Halbsguth A, et al. Successful treatment with adalimumab in infliximab-resistant Crohn's disease. J Gastroenterol Hepatol. 2005; 20: 1464-1465. (Pubitemid 43960853)
135. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005; 100: 75-79. (Pubitemid 41623272)
136. Oussalah A, Babouri A, Chevaux JB, et al. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther. 2009; 29: 416-423.
137. Hinojosa J, Gomollon F, Garcia S, et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre tria. Aliment Pharmacol Ther. 2007; 25: 409-418. (Pubitemid 46184454)
138. Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010; 31: 92-101.
139. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005; 353: 1912-1925. (Pubitemid 41565956)
140. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007; 132: 1672-1683. (Pubitemid 46695722)
141. Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther. 2001; 15: 371-377. (Pubitemid 32187559)
142. Tamaki H, Nakase H, Matsuura M, et al. The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn's disease. J Gastroenterol. 2008; 43: 774-779.
143. Ng SC, Arebi N, Kamm MA,. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 129-134. (Pubitemid 46806220)
144. Plamondon S, Ng SC, Kamm MA,. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. Aliment Pharmacol Ther. 2007; 25: 557-567.
145. Kane SV, Chao J, Mulani PM,. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther. 2009; 26: 936-946.
146. Vermeire S, Van Assche G, Rutgeerts P,. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: 661-665. (Pubitemid 39276479)
147. Ryan ER, Heaslip IS,. Magnetic resonance enteroclysis compared with conventional enteroclysis and computed tomography enteroclysis: a critically appraised topic. Abdom Imaging. 2008; 33: 34-37.
148. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005; 21: 733-738. (Pubitemid 40469001)
149. Katz JA,. Pregnancy and inflammatory bowel disease. Curr Opin Gastroenterol. 2004; 20: 328-332. (Pubitemid 38813673)
150. Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006; 4: 1255-1258. (Pubitemid 44512222)
151. Mahadevan U, Martin C, Sandler R,. One year newborn outcomes among offspring of women with inflammatory bowel disease: the Piano Registry. Gastroenterology. 2010; 764.
152. Gisbert JP,. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis. 2010; 16: 881-895.
153. Pelletier AL, Kalisazan B, Wienckiewicz J, et al. Infliximab treatment for symptomatic Crohn's disease strictures. Aliment Pharmacol Ther. 2009; 29: 279-285.
154. Holtmann M, Wanitschke R, Helisch A, et al. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease.] Z Gastroenterol. 2003; 41: 11-17. (Pubitemid 36168319)
155. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009; 136: 441-450.
156. Regueiro M, Kip KE, Schraut W,. 4.5 year follow up of patients enrolled in the randomised controlled trial of infliximab for prevention of post operative Crohn's recurrence. Gastroenterology. 2010; W1298.
157. Ng SC, Kamm MA,. Management of postoperative Crohn's disease. Am J Gastroenterol. 2008; 103: 1029-1035. (Pubitemid 351501118)
158. Sorrentino D, Paviotti A, Terrosu G, et al. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol. 2010; 8: 591-599.